Mesoblast Limited (MSB.AX)
AUD 3.05
(54.04%)
AUD 3.05
(54.04%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 | 669.15 Million USD | -0.04% |
| 2023 | 669.41 Million USD | 1.1% |
| 2022 | 662.14 Million USD | -11.09% |
| 2021 | 744.71 Million USD | 1.52% |
| 2020 | 733.6 Million USD | 12.5% |
| 2019 | 652.11 Million USD | -5.82% |
| 2018 | 692.44 Million USD | 5.61% |
| 2017 | 655.68 Million USD | -4.14% |
| 2016 | 684.01 Million USD | -32.8% |
| 2015 | 1.01 Billion USD | 13.19% |
| 2014 | 899.31 Million USD | 1.77% |
| 2013 | 883.71 Million USD | 22.66% |
| 2012 | 720.45 Million USD | -5.61% |
| 2011 | 763.25 Million USD | 1831.56% |
| 2010 | 39.51 Million USD | 46.49% |
| 2009 | 26.97 Million USD | -2.93% |
| 2008 | 27.78 Million USD | 30.84% |
| 2007 | 21.23 Million USD | 29.62% |
| 2006 | 16.38 Million USD | -23.67% |
| 2005 | 21.46 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 670.28 Million USD | 0.13% |
| 2024 FY | 669.15 Million USD | -0.04% |
| 2024 Q4 | 669.15 Million USD | 0.0% |
| 2024 Q2 | 670.28 Million USD | 0.0% |
| 2023 Q2 | 668.06 Million USD | -2.4% |
| 2023 Q4 | 669.41 Million USD | 2.92% |
| 2023 FY | 669.41 Million USD | 1.1% |
| 2023 Q3 | 650.44 Million USD | -2.64% |
| 2023 Q1 | 684.49 Million USD | 3.38% |
| 2022 Q2 | 704.43 Million USD | -2.41% |
| 2022 Q1 | 721.81 Million USD | -3.07% |
| 2022 Q3 | 681.68 Million USD | -3.23% |
| 2022 Q4 | 662.14 Million USD | -2.87% |
| 2022 FY | 662.14 Million USD | -11.09% |
| 2021 Q3 | 766.12 Million USD | 11.47% |
| 2021 FY | 744.71 Million USD | 1.52% |
| 2021 Q1 | 712.57 Million USD | -2.87% |
| 2021 Q2 | 687.31 Million USD | -3.55% |
| 2021 Q4 | 744.71 Million USD | -2.79% |
| 2020 Q1 | 653.78 Million USD | 0.26% |
| 2020 Q2 | 690.23 Million USD | 5.58% |
| 2020 Q3 | 665.79 Million USD | -3.54% |
| 2020 Q4 | 733.6 Million USD | 10.19% |
| 2020 FY | 733.6 Million USD | 12.5% |
| 2019 Q4 | 652.11 Million USD | -3.49% |
| 2019 Q3 | 675.7 Million USD | -1.83% |
| 2019 Q2 | 688.33 Million USD | -0.07% |
| 2019 Q1 | 688.78 Million USD | -0.53% |
| 2019 FY | 652.11 Million USD | -5.82% |
| 2018 Q4 | 692.44 Million USD | 2.15% |
| 2018 FY | 692.44 Million USD | 5.61% |
| 2018 Q3 | 677.85 Million USD | 1.96% |
| 2018 Q2 | 664.81 Million USD | -1.05% |
| 2018 Q1 | 671.89 Million USD | 2.47% |
| 2017 Q1 | 665.44 Million USD | -2.72% |
| 2017 FY | 655.68 Million USD | -4.14% |
| 2017 Q4 | 655.68 Million USD | -3.46% |
| 2017 Q3 | 679.16 Million USD | 2.77% |
| 2017 Q2 | 660.88 Million USD | -0.69% |
| 2016 Q2 | 790.95 Million USD | 5.06% |
| 2016 Q1 | 752.86 Million USD | -26.04% |
| 2016 FY | 684.01 Million USD | -32.8% |
| 2016 Q4 | 684.01 Million USD | -11.18% |
| 2016 Q3 | 770.14 Million USD | -2.63% |
| 2015 Q2 | 964.58 Million USD | 18.08% |
| 2015 Q1 | 816.85 Million USD | -9.17% |
| 2015 FY | 1.01 Billion USD | 13.19% |
| 2015 Q4 | 1.01 Billion USD | 0.0% |
| 2015 Q3 | - USD | -100.0% |
| 2014 Q3 | 833.81 Million USD | -16.71% |
| 2014 FY | 899.31 Million USD | 1.77% |
| 2014 Q2 | 1 Billion USD | 0.0% |
| 2014 Q1 | - USD | -100.0% |
| 2014 Q4 | 899.31 Million USD | 7.86% |
| 2013 Q3 | 919.81 Million USD | 35.18% |
| 2013 FY | 883.71 Million USD | 22.66% |
| 2013 Q4 | 883.71 Million USD | -3.92% |
| 2013 Q1 | 706 Million USD | -2.01% |
| 2013 Q2 | 680.41 Million USD | -3.62% |
| 2012 FY | 720.45 Million USD | -5.61% |
| 2012 Q4 | 720.45 Million USD | 0.0% |
| 2011 FY | 763.25 Million USD | 1831.56% |
| 2010 FY | 39.51 Million USD | 46.49% |
| 2009 FY | 26.97 Million USD | -2.93% |
| 2008 FY | 27.78 Million USD | 30.84% |
| 2007 FY | 21.23 Million USD | 29.62% |
| 2006 FY | 16.38 Million USD | -23.67% |
| 2005 FY | 21.46 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| EZZ Life Science Holdings Limited | 25.55 Million AUD | -2518.791% |
| Anatara Lifesciences Ltd | 1.67 Million AUD | -39934.952% |
| Zelira Therapeutics Limited | 5.18 Million AUD | -12809.496% |
| Biome Australia Limited | 8.27 Million AUD | -7984.692% |
| Patrys Limited | 4.16 Million AUD | -15979.302% |
| Orthocell Limited | 26.61 Million AUD | -2414.175% |
| Imugene Limited | 151.39 Million AUD | -341.983% |
| Noxopharm Limited | 6.78 Million AUD | -9764.046% |
| PYC Therapeutics Limited | 91.23 Million AUD | -633.408% |
| Chimeric Therapeutics Limited | 15.27 Million AUD | -4281.237% |
| Prescient Therapeutics Limited | 20.39 Million AUD | -3181.312% |
| Proteomics International Laboratories Limited | 10.87 Million AUD | -6053.068% |
| Cynata Therapeutics Limited | 8.38 Million AUD | -7877.228% |
| CSL Limited | 56.93 Billion AUD | 98.825% |
| Arovella Therapeutics Limited | 13.28 Million AUD | -4937.026% |
| Bio-Gene Technology Limited | 3.15 Million AUD | -21078.476% |
| Clinuvel Pharmaceuticals Limited | 231.12 Million AUD | -189.522% |
| Starpharma Holdings Limited | 36.81 Million AUD | -1717.659% |
| Nanollose Limited | 241.95 Thousand AUD | -276465.503% |
| Memphasys Limited | 12.43 Million AUD | -5283.307% |
| Invex Therapeutics Ltd | 6.12 Million AUD | -10833.781% |
| NeuroScientific Biopharmaceuticals Limited | 5.43 Million AUD | -12209.945% |
| Amplia Therapeutics Limited | 14.84 Million AUD | -4407.566% |
| Botanix Pharmaceuticals Limited | 112.46 Million AUD | -494.99% |
| Island Pharmaceuticals Limited | 2.56 Million AUD | -25993.218% |
| Race Oncology Limited | 20.22 Million AUD | -3207.959% |
| Nyrada Inc. | 5.9 Million AUD | -11227.632% |
| Telix Pharmaceuticals Limited | 398.3 Million AUD | -68.001% |
| Dimerix Limited | 32.07 Million AUD | -1985.983% |
| PharmAust Limited | 11.12 Million AUD | -5914.94% |
| Immutep Limited | 147.44 Million AUD | -353.82% |
| Clarity Pharmaceuticals Ltd | 154.62 Million AUD | -332.747% |
| Alterity Therapeutics Limited | 19.22 Million AUD | -3380.867% |
| BTC Health Limited | 5.14 Million AUD | -12896.273% |
| Acrux Limited | 8.96 Million AUD | -7365.726% |
| Neuren Pharmaceuticals Limited | 247.97 Million AUD | -169.852% |
| Biotron Limited | 493.47 Thousand AUD | -135499.908% |
| Tissue Repair Ltd | 19.38 Million AUD | -3351.096% |
| AdAlta Limited | 5.57 Million AUD | -11907.05% |
| Radiopharm Theranostics Limited | 72.03 Million AUD | -828.91% |
| Hexima Limited | 2.26 Million AUD | -29391.045% |
| AnteoTech Limited | 9.38 Million AUD | -7032.93% |
| Paradigm Biopharmaceuticals Limited | 27.39 Million AUD | -2343.017% |
| Recce Pharmaceuticals Ltd | 6.36 Million AUD | -10405.393% |
| Avecho Biotechnology Limited | 7.31 Million AUD | -9042.296% |
| Actinogen Medical Limited | 21.31 Million AUD | -3039.814% |
| Immuron Limited | 15.54 Million AUD | -4203.243% |
| Argenica Therapeutics Limited | 16.37 Million AUD | -3985.793% |